- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00280345
Autoimmune Dysregulation in Pigmentary Glaucoma
Study Overview
Status
Intervention / Treatment
Detailed Description
The aim is to establish, through tissue and aqueous analysis of patients with pigmentary glaucoma, POAG and normal controls, that markers for anterior chamber autoimmune dysfunction occur in significantly different amounts in patients with these conditions when compared to normal controls. We also will attempt to establish, through proven methodologies of tissue gene expression, that the source of these differences in markers, notably PEDF and IL-18, is from the uveal tissues of the anterior chamber, most importantly the iris and possibly the trabecular meshwork as well.
The actual etiology at the cellular level of elevated intraocular pressure and the development of pigmentary glaucoma is not well understood in humans. If anterior chamber immune dysfunction were shown to be an important factor in the development of this disease in humans, which apparently is demonstrated by the DBA/2J mouse, it would lead to an important area of further investigation and possible novel approaches in treating or preventing this disease in humans.
We hypothesize that in patients with pigmentary glaucoma, the amount of PEDF in the aqueous is significantly reduced while IL-18 is significantly elevated when compared to the aqueous of normal controls. In patients with POAG, we hypothesize similar results for PEDF, although significantly less reduction of PEDF when compared to the pigmentary glaucoma patients may be an interesting finding as well. With regard to IL-18, it is possible that amounts would be significantly elevated in the pigmentary glaucoma patients when compared to both normal controls and POAG patients. In view of the results from the DBA/2J mouse model, we hope to determine whether expression of PEDF could be down regulated in the iris and/or trabecular meshwork of pigmentary glaucoma patients when compared to POAG patients and whether IL-18 expression in these tissues could be up regulated in pigmentary glaucoma patients when compared to POAG patients.
Such findings would strongly suggest that anterior chamber immune abnormalities play a role in the etiology of pigmentary glaucoma in humans. It already has been suggested that decreased amounts and expression of PEDF are found in patients with glaucoma and other neurodegenerative diseases of the eye. However, the source of the decreased expression has not been identified. If IL-18 production is elevated in pigmentary glaucoma and is up regulated in the anterior chamber structures of the eye in human patients with the disease, this also would be highly suggestive that localized anterior chamber immune dysfunction plays a role in the development of this disease.
Depending on our findings, additional investigations of autoimmune dysregulation in pigmentary glaucoma (and perhaps other secondary glaucomas) may help determine the predictive value of such markers in identifying whether or not patients with pigment dispersion syndrome develop glaucomatous damage.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Dean A. McGee Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patients in the study will be between 18 and 85 years old. To prevent any possibility that previous manipulation of the iris and uveal structures may affect results of the assays, patients with any previous intraocular surgery or laser iridotomies will be excluded. Patients who have undergone laser trabeculoplasty within 90 days of surgery also will be excluded. In the normal controls undergoing cataract surgery, patients with signs of pigment dispersion syndrome or exfoliation syndrome without glaucoma will be excluded from the study.
Additional Inclusion Criteria:
- In the glaucoma patients, visual field and/or optic disc changes characteristic of glaucoma.
- Ability to comprehend the information describing the clinical study.
- Ability to provide signed and dated IRB-approved informed consent (ICF) for the study.
Exclusion Criteria:
- Any clinically significant uncontrolled medical condition(s) that might, in the investigators' opinion, interfere with the assessment.
- Use of corticosteroids within 3 months prior to surgery.
- Use of systemic anti-metabolites within 6 weeks prior to surgery.
- Use of any investigational drug within 4 weeks prior to surgery.
Specific to the study eye exclusions:
- History of non-iatrogenic uveitis or active uveitis.
- Discernible congenital abnormality of the anterior chamber structures.
- Neovascular, uveitic, traumatic, or infantile glaucoma.
- Proliferative or severe non-proliferative diabetic retinopathy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Autoimmune Dysergulation in Pigmentary Glaucoma
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Crystal McAfee, MA-HHSA, Dean A. McGee Eye Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pigmentary Glaucoma
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open Angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Glaucot Teknoloji Anonim SirketiRecruitingPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
Clinical Trials on Trabeculectomy
-
Sunnybrook Health Sciences CentreCompletedGlaucoma | Corneal Endothelial Cell LossCanada
-
Shanghai Eye Disease Prevention and Treatment CenterUnknown
-
University of ZurichCompleted
-
Assiut UniversityUnknownGlaucoma | Angle Closure Glaucoma | Cataract SecondaryEgypt
-
Queen's UniversityGlaucoma Research & Education GroupWithdrawn
-
Helsinki University Central HospitalRecruitingNormal Tension GlaucomaFinland
-
University of California, San FranciscoSeva Foundation; Lumbini Eye Institute and HospitalUnknown
-
University of TorontoCompleted